Funding Momentum Vivace has recently closed a $35M Series D led by RA Capital, boosting pre-money valuation to $90M, indicating strong investor confidence and potential capital for collaborations, partnerships, or licensing deals in oncology.

Hippo-YAP Focus The company targets first‑in‑class cancer therapies via the Hippo-YAP pathway, presenting a clear niche for partnerships with biologics or small molecule discovery platforms, contract research, or co‑development opportunities to accelerate clinical milestones.

Early-Stage Scale With 11–50 employees and recent funding, Vivace is in an expansion phase, offering channel for strategic collaborations, CRO/CGO services, and technology licensing to accelerate pipeline progress and reach clinical milestones.

Clinical & Market Potential A focused pipeline around YAP-TEAD transcription inhibition aligns with growing oncology demand for novel cell proliferation regulators, suggesting opportunities for joint ventures, strategic investments, and priority access agreements in oncology markets.

Founders & Network Scientific leadership from UCSD/UCSF founders plus visibility through multiple news outlets creates potential for partnering with academic medical centers, co‑development discussions, and access to clinician networks for trial sites and translational studies.